Abstract Number: 1012 • 2019 ACR/ARP Annual Meeting
Apremilast Inhibits Immune Cells Support of Inflammatory Osteoclastogenesis
Background/Purpose: PsA is associated with bone erosion and inflammation-induced bone loss. This process is mediated by osteoclasts, and modulated by inflammatory cytokines (i.e. TNF, IL-1,…Abstract Number: 1446 • 2019 ACR/ARP Annual Meeting
Golimumab as First, Second or at Least Third Biologic Agent in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Post Hoc Analysis of a Non-Interventional Study in Germany
Background/Purpose: The aim of this post hoc analysis is to assess effectiveness of GLM used as first, second, or at least third biologic agent in…Abstract Number: 1500 • 2019 ACR/ARP Annual Meeting
Effectiveness of Switching Between TNF Inhibitors in Patients with Axial Spondyloarthritis: Is the Reason to Switch Relevant?
Background/Purpose: Over the last years, and mostly due to lack of alternatives, it has been common practice to start a second TNF inhibitor (TNFi) in…Abstract Number: 1776 • 2019 ACR/ARP Annual Meeting
Causal Effect of TNF-α, IL-12p70, IL-17 Levels on the Risk of Psoriatic Arthritis: A Mendelian Randomization Study
Background/Purpose: Biologic agents targeting cytokines including TNF-α, IL-12p70 and IL-17 have been proven to be very effective in treating psoriatic arthritis (PsA). Nonetheless, whether these…Abstract Number: 2476 • 2019 ACR/ARP Annual Meeting
Side Effects of Methotrexate and TNFi: Differences in Tolerability Among Patients with PsA and RA
Background/Purpose: Methotrexate (MTX) is generally well tolerated in rheumatoid arthritis (RA) but little is known about the tolerability of MTX in psoriatic arthritis (PsA). One…Abstract Number: 94 • 2019 ACR/ARP Annual Meeting
Tumor Necrosis Factor Receptor 2 Signaling Potentiates Proliferation and Suppressive Activities of Follicular Regulatory T Cells
Background/Purpose: Tumor Necrosis Factor (TNF) α is a multifunctional cytokine with pro-inflammatory and anti-inflammatory characteristics. Regulatory T cells (Treg) express a remarkably high level of…Abstract Number: 1871 • 2013 ACR/ARHP Annual Meeting
Progranulin Directly Binds To The CRD 2 and CRD3 Of TNFR Extracellular Domains
Background/Purpose: We previously reported that Progranulin (PGRN) bound to TNF receptors (TNFR) and was therapeutic in inflammatory arthritis (Tang, W., et al, Science, 2011). PGRN…Abstract Number: 1365 • 2012 ACR/ARHP Annual Meeting
Double-Blind, Placebo-Controlled, 28-Week Trial of Efficacy and Safety of Infliximab Plus Naproxen Vs Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with Early, Active Axial Spondyloarthritis Trial, Part I
Background/Purpose: Efficacy of anti–tumor necrosis factor (TNF) therapy in patients with axial spondyloarthritis (SpA) has been tested only in patients who are refractory to NSAIDs.…Abstract Number: 834 • 2012 ACR/ARHP Annual Meeting
Cetrorelix, a Gonadotropin-Releasing Hormone Antagonist, Significantly Reduces Tumour-Necrosis-Factor-Alpha and Demonstrates Efficacy in Patients with Active Rheumatoid Arthritis: A Proof-of-Concept, Double-Blind, Randomised Trial
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is unclear, and treatment options can be improved. Gonadotropin-releasing hormone (GnRH) stimulates immune responses (1) and therefore might…Abstract Number: 779 • 2012 ACR/ARHP Annual Meeting
Changes in Active Inflammatory Lesions Assessed by Magnetic Resonance Imaging: Results of the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial
Background/Purpose: Few studies have evaluated changes in active inflammation of spine and sacroiliac (SI) joints by MRI during long-term treatment for axial SpA, and no…Abstract Number: 549 • 2012 ACR/ARHP Annual Meeting
A Randomized, Open-Label Study of Maintenance of Partial Remission with Naproxen Vs No Treatment: Results of the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial, Part II
Background/Purpose: In patients with axial SpA who have achieved partial remission, it is unclear whether continuous treatment with NSAIDs is superior to stopping treatment. Objectives:…Abstract Number: 471 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Golimumab As Add-On Therapy to Disease-Modifying Antirheumatic Drugs
Background/Purpose: This study evaluated golimumab (GLM) as add-on therapy in patients with active RA despite treatment with non-biologic DMARDs. Two GLM treatment strategies (subcutaneous [SC]…Abstract Number: 472 • 2012 ACR/ARHP Annual Meeting
More Positive Expectations of Treatment with Golimumab for Rheumatoid Arthritis Are Associated with Greater Improvement in Clinical Outcomes
Background/Purpose: Little is known about how patient and physician expectations relate to clinical outcomes. This study investigated the expectations that patients and physicians have at…
- « Previous Page
- 1
- …
- 4
- 5
- 6